Carbon Ion Radiotherapy for Recurrent Gliomas (CINDERELLA)
|ClinicalTrials.gov Identifier: NCT01166308|
Recruitment Status : Unknown
Verified February 2013 by Stephanie Combs, University Hospital Heidelberg.
Recruitment status was: Recruiting
First Posted : July 21, 2010
Last Update Posted : February 20, 2013
Treatment of patients with recurrent glioma includes neurosurgical resection, chemotherapy, or radiation therapy. In most cases, a full course of radiotherapy has been applied after primary diagnosis, therefore application of re-irradiation has to be applied cautiously. With modern precision photon techniques such as fractionated stereotactic radiotherapy (FSRT), a second course of radiotherapy is safe and effective and leads to survival times of 22, 16 and 8 months for recurrent WHO grade II, III and IV tumors.
Carbon ions offer physical and biological characteristics. Due to their inverted dose profile and the high local dose deposition within the Bragg peak precise dose application and sparing of normal tissue is possible. Moreover, in comparison to photons, carbon ions offer an increase relative biological effectiveness (RBE), which can be calculated between 2 and 5 depending on the Glioblastoma (GBM) cell line as well as the endpoint analyzed. Protons, however, offer an RBE which is comparable to photons.
First Japanese Data on the evaluation of carbon ion radiation therapy for the treatment of primary high-grade gliomas showed promising results in a small and heterogeneous patient collective.
In the current Phase I/II-CINDERELLA-trial re-irradiation using carbon ions will be compared to FSRT applied to the area of contrast enhancement representing high-grade tumor areas in patients with recurrent gliomas. Within the Phase I Part of the trial, the Recommended Dose (RD) of carbon ion radiotherapy will be determined in a dose escalation scheme. In the subsequent randomized Phase II part, the RD will be evaluated in the experimental arm, compared to the standard arm, FSRT with a total dose of 36 Gy in single doses of 2 Gy.
Primary endpoint of the Phase I part is toxicity. Primary endpoint of the randomized part II is survival after re-irradiation at 12 months, secondary endpoint is progression-free survival.
|Condition or disease||Intervention/treatment||Phase|
|Glioma||Radiation: Carbon Ion Radiotherapy Radiation: Fractionated Stereotactic Radiotherapy (FSRT)||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||436 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Randomised Phase I/II Study to Evaluate Carbon Ion Radiotherapy Versus Fractionated Stereotactic Radiotherapy in Patients With Recurrent or Progressive Gliomas: The CINDERELLA Trial|
|Study Start Date :||August 2010|
|Estimated Primary Completion Date :||July 2014|
|Estimated Study Completion Date :||August 2015|
Experimental: Carbon Ion Radiotherapy
Carbon Ion Radiotherapy in the RD determined within the Phase I Part of the Trial
Radiation: Carbon Ion Radiotherapy
Carbon Ion Radiotherapy in the RD determined within the Phase I part of the Study (10 x 3Gy E to 16 x 3 Gy E)
Active Comparator: Standard Treatment: Fractionated Stereotacitc Radiotherapy
Standard Precision Radiotherapy performed as Fractionated Stereotactic Radiotherapy (FSRT) up to 36 Gy in single dosis of 2 Gy
Radiation: Fractionated Stereotactic Radiotherapy (FSRT)
Standard Treatment as Re-Irradiation performed as Fractionated Stereotactic Radiotherapy (FSRT)up to 36 Gy in single doses of 2 Gy
- Overall Survival [ Time Frame: at 12 months ]
- Progression-free Survival
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01166308
|Contact: Stephanie E Combs, MD||+49-6221-56 ext firstname.lastname@example.org|
|Contact: Jürgen Debus, MD PhD||+49-6221-56 ext email@example.com|
|University Hospital of Heidelberg, Department of Radiation Oncology||Recruiting|
|Heidelberg, Germany, 69120|
|Sub-Investigator: Stephanie E Combs, MD|
|Principal Investigator: Jürgen Debus, MD PhD|